Most non-small cell lung cancers (NSCLC) treated with the standard therapy erlotinib (a drug used to treat cancers with a mutated form of the epidermal growth factor receptor, or EGFR) eventually come back or continue to grow despite this treatment. In many patients, the resistance to EGFR inhibitors like erlotinib is due to a mutation called EGFR T790M.
In this study, researchers are evaluating the safety and effectiveness of an investigational drug called CO-1686 in patients with NSCLC that contain an EGFR T790M mutation. CO-1686 targets cancer cells containing this mutation. Doctors hope it will be effective in patients whose NSCLC has stopped responding to erlotinib or other EGFR inhibitors.
CO-1686 is a pill that is taken orally (by mouth) twice a day.